Epratuzumab for systemic lupus erythematosus

Lupus

Volumn 22, Issue 4, 2013, Pages 400-405

  Wallace, D J ^a   Goldenberg, D M ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

B cells; BILAG; CD22; epratuzumab; immunotherapy; systemic lupus erythematosus

Indexed keywords

CD22 ANTIGEN; EMAB; EPRATUZUMAB; METHYLPREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DRUG DOSE INCREASE; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84875933771     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312469692     Document Type: Article

References (35)

1. Dörner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther. 2009 ; 11: 247-247
2. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006 ; 6: 1341-1353
3. Perosa F, Prete M, Racanelli V, Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med. 2013 ; 267: 260-277
4. Thanou-Stavraki A, Sawalha AH. An update on belimumab for the treatment of lupus. Biologics. 2011 ; 5: 33-43
5. Dörner T, Goldenberg DM. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Therapeut Clin Risk Management. 2007 ; 3: 953-959
6. Traczewski P, Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol. 2011 ; 71: 175-182
7. Dörner T, Shock A, Smith KGC. CD22 and autoimmune disease. International Reviews of Immunology. 2012 ; 31: 363-378
8. Wilson GL, Fox CH, Fauci AS, Kehrl JH. CDNA cloning of the B-cell membrane protein CD22: a mediator of B-B-cell interactions. J Exp Med. 1991 ; 173: 137-146
9. Engel P, Wagner N, Miller A, Tedder TF. Identification of the ligand binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med. 1995 ; 181: 1581-1586
10. Wilson GL, Najfeld V, Kozlow E, et al. Genomic structure and chromosomal mapping of the human CD22 gene. J Immunol. 1993 ; 150: 5013-5024
11. Dörken B, Moldenhauer G, Pezzutto A, et al. Hd39 (B3), a B-lineage-restricted antigen whose cell-surface expression is limited to resting and activated human lymphocytes-B. J Immunol. 1986 ; 136: 4470-4479
12. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opinion Immunol. 2005 ; 17: 290-297
13. Tedder TF, Poe JC, Haas KM. CD22: A multifunctional receptor that regulates B-lymphocyte survival and signal transduction. Adv Immunol. 2005 ; 88: 1-50
14. Doody GM, Justement LB, Delibrias CC, et al. A role in B-cell activation for CD22 and the protein-tyrosine-phosphatase Shp. Science. 1995 ; 269: 242-244
15. Chaouchi N, Vazquez A, Galanaud P, Leprince C. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol. 1995 ; 154: 3096-3104
16. Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood. 1999 ; 94: 1382-1393
17. Stein R, Belisle E, Hansen HJ, et al. Epitope specificity of the anti-(B-cell lymphoma) monoclonal antibody, LL2. Cancer Immunol. Immunother. 1993 ; 37: 2938-2938
18. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, et al. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res. 1989 ; 49: 4568-4577
19. Shih LB, Lu HHZ, Xuan H, et al. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer. 1994 ; 56: 538-545
20. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal anatibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003 ; 9: 3982S - 3990S
21. Carnahan J, Stein R, Qu ZX, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007 ; 44: 1331-1341
22. Stein R, Qu ZX, Chen S, et al. Characterization of a new humanized anati-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res. 2004 ; 10: 2868-2878
23. Dörner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006 ; 8: R74 - R74
24. Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2008 ; 67: 450-457
25. Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2013 ; 12: R204 - R204
26. www.clinicaltrials.gov (accessed March 2012).
27. Petri M, Hobbs K, Gordon C, et al. Randomized controlled trials of epratuzumab (anti CD22 MAB targeting B cells) reveal clinically meaningful improvements in patients with moderate/severe flares. Ann Rheum Dis. 2008 ; 67: 53-53
28. Wallace D, Hobbs K, Houssiau F, et al. Randomized controlled trials of epratuzumab (anti CD22 MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients. Ann Rheum Dis. 2008 ; 67: 212-212
29. Strand V, Gordon C, Kalunian K, et al. Randomized controlled trials of epratuzumab (Anti-CD22 MAB targeting B-cells) show meaningful improvements in health related quality of life (HRQOL) in SLE patients with high disease activity and low baseline self-report measures. Ann Rheum Dis. 2008 ; 67: 212-212
30. Strand V, Kalunian K, Wallace DJ, et al. Epratuzumab-treated SLE patients report improvements in health-related quality of life: interim results from a US open-label extension study. EULAR 2012, abstract AB0633.
31. Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM, a Phase IIb study. Arthritis Rheum. 2013 ; 62: S605 - S605
32. Kalunian KC, Wallace DJ, Petri MA, et al. BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: Results from EMBLEM, a Phase III study. Arthritis Rheum. 2013 ; 62: S190 - S190
33. Hobbs, K., Houssiau, F., Kelley, L., Kilgallen, B. and Bongardt, S. Safety profile of epratuzumab in patients with moderate-to-severe Systemic Lupus Erythematosus (SLE): preliminary results. The European Congress of Rheumatology (EULAR), May 25-28, 2011, London, UK: abstract THU0425.
34. Wallace DJ, Strand V, Furie R, Petri M, Kalunian K, Pike M, et al. Evaluation of treatment success in systemic lupus erythematosus clinical trials: Development of the British Isles Assessment Group-Based Composite Lupus Assessment Endpoint. Arthritis Rheum. 2011 ; 63: 665-666
35. Wallace DJ, Kalunian K, Petri M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicenter study. Annals of the Rheumatic Diseases Online First, 12 January 2013. DOI: 10.1136/annrheumdis-2012-202760.